NCT06932081 Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
| NCT ID | NCT06932081 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Leiden University Medical Center |
| Condition | Adult Congenital Heart Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2023-01-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Eligibility Criteria
Inclusion Criteria: * Congenital heart defect. * Age ≥ 18 years. * Initiated on treatment with an SGLT2i. Exclusion Criteria: \- No consent for data collection.
Contact & Investigator
Anastasia D. Egorova, MD PhD
PRINCIPAL INVESTIGATOR
Leiden University Medical Center
Frequently Asked Questions
Who can join the NCT06932081 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Adult Congenital Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06932081 currently recruiting?
Yes, NCT06932081 is actively recruiting participants. Contact the research team at r.m.l.neijenhuis@lumc.nl for enrollment information.
Where is the NCT06932081 trial being conducted?
This trial is being conducted at Baltimore, United States, Grand Rapids, United States, New York, United States, Duisburg, Germany and 7 additional locations.
Who is sponsoring the NCT06932081 clinical trial?
NCT06932081 is sponsored by Leiden University Medical Center. The principal investigator is Anastasia D. Egorova, MD PhD at Leiden University Medical Center. The trial plans to enroll 400 participants.